UCSF, Optivia Get $430K Grant for ADME Tool Development | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The University of California, San Francisco, and Optivia Biotechnology today said that they have received a $430,000 Phase I Small Business Innovation Research grant to develop a system for characterizing the role transporter proteins play in the disposition of drugs by the liver.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.